Pediatrix Medical (MD) Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Stable same-facility patient volume growth, inorganic initiatives and transition to an RCM structure should aid MD's future growth.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

MD expects transformational and restructuring-related expenses to be $48 million in 2024.

Pediatrix Medical Group, Inc. (NYSE:MD ) Q3 2024 Earnings Conference Call November 1, 2024 9:00 AM ET Company Participants Charles Lynch - Senior Vice President, Finance and Strategy James Swift - Chief Executive Officer Kasandra Rossi - Executive Vice President, Chief Financial Officer and Treasure Conference Call Participants Jack Senft - William Blair Jack Slevin - Jefferies A.J. Rice - UBS Operator Ladies and gentlemen, thank you for standing by and welcome to the 2024 Third Quarter's Earnings Conference.

Pediatrix Medical Group (MD) came out with quarterly earnings of $0.44 per share, beating the Zacks Consensus Estimate of $0.37 per share. This compares to earnings of $0.32 per share a year ago.

Pediatrix Medical Group (MD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Pediatrix Medical Group 2024 Third Quarter Conference Call/Webcast Scheduled for Friday, November 1, 2024.

MD remains one of the best-positioned pediatric service providers with favorable valuation to achieve margin improvement.